Sign up now to receive our regular news briefs.

Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,'” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.

2 Comments

  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition. Comments written in all caps will be deleted.


Current day month ye@r *

More...

  • Features World Graves of Jewish Pirates in Jamaica Give Caribbean Tourists Taste of Little-Known History

    Graves of Jewish Pirates in Jamaica Give Caribbean Tourists Taste of Little-Known History

    Tour operators are calling attention to Jamaica’s little-known Jewish heritage by arranging visits to historic Jewish sites on the Caribbean island, including a cemetery where Jewish pirates are buried. A report in Travel and Leisure magazine describes the Hunts Bay Cemetery in Kingston, where there are seven tombstones engraved with Hebrew benedictions and skull and crossbones insignia. According to the report, centuries ago, Jewish pirates sailed the waters of Jamaica and settled in Port Royal. The town, once known as “the wickedest city in the […]

    Read more →
  • Arts and Culture Blogs Filmmaker Eyal Resh Embraces the Challenge of Telling Israel’s Story (VIDEO)

    Filmmaker Eyal Resh Embraces the Challenge of Telling Israel’s Story (VIDEO)

    JNS.org – Telling Israel’s story. It’s the specific title of a short film that Eyal Resh created last year. It’s also the theme behind the 27-year-old Israeli filmmaker’s broader body of work. The widely viewed “Telling Israel’s Story” film—directed by Resh for a gala event hosted by the Times of Israel online news outlet—seemingly begins as a promotional tourism video, but quickly evolves to offer a multilayered perspective. “I want to tell you a story about a special place for me,” a young woman whispers […]

    Read more →
  • Blogs Features Israel Geeks Out: Science, Art and Tech Event Embodies Jewish State’s ‘DNA’

    Israel Geeks Out: Science, Art and Tech Event Embodies Jewish State’s ‘DNA’

    JNS.org – The entrance to Jerusalem’s Sacher Park was transformed from April 25-27 by a fire-breathing robotic dragon, which flailed its arms and attempted to take flight. The robot, a signature feature at Jerusalem’s first-ever “Geek Picnic,” was one of more than 150 scientific amusements available for the public to experience. This particular dragon was designed by students from Moscow’s Art Industrial Institute in conjunction with the Flacon design factory, said Anatasia Shaminer, a student who helped facilitate the display. Children […]

    Read more →
  • Book Reviews Opinion The Syrian Virgin (REVIEW)

    The Syrian Virgin (REVIEW)

    The Syrian Virgin, by Zack Love. CreateSpace, 2015. The Syrian Virgin, by Zack Love, is a very interesting novel. Equally a political and romantic thriller, at times a real page-turner, it gets you intimately involved in the dire situation in today’s Syria, as well as in the romantic entanglements of its mostly New York-based characters — whose entanglements just might determine the fate of that dire situation in Syria. Along the way it introduces a really important idea that somehow […]

    Read more →
  • Features Unpacking the Nagorno-Karabakh Conflict and Its Ripple Effect on Israel’s Region

    Unpacking the Nagorno-Karabakh Conflict and Its Ripple Effect on Israel’s Region

    JNS.org – Aside from Israel itself, those with a vested interest in the Jewish state are accustomed to tracking developments related to Middle East players such as Iran, Syria, Jordan and Egypt. But much global attention has recently focused on the Caucasus region at the Europe-Asia border, specifically on the suddenly intensified violence between Azerbaijan and Armenia in the mountainous Nagorno-Karabakh area of western Azerbaijan. The Nagorno-Karabakh conflict, while not taking place in Israel’s immediate neighborhood, does have what one scholar called […]

    Read more →
  • Blogs Features Earth Day 2016: Israel Shines in Water Technology, Recycling, Renewable Energy

    Earth Day 2016: Israel Shines in Water Technology, Recycling, Renewable Energy

    JNS.org – On Friday, April 22, 196 nations across the world mark Earth Day, the annual day dedicated to environmental protection that was enacted in 1970. Not to be forgotten on this day is Israel, which is known as the “start-up nation” for its disproportionate amount of technological innovation, including in the area of protecting the environment. For Earth Day 2016, JNS.org presents a sampling of the Jewish state’s internal achievements and global contributions in the environmental realm. Water conservation Israeli […]

    Read more →
  • Arts and Culture World New Documentary Explores Holocaust Humor, Role That Laughter Played in Death Camps

    New Documentary Explores Holocaust Humor, Role That Laughter Played in Death Camps

    Holocaust humor and the role that laughter played in the lives of Jews during World War II are the focus of a documentary that made its world premiere on Monday at the Tribeca Film Festival in New York City. In The Last Laugh, first- and second-generation survivors, as well as famous Jewish and non-Jewish comedians, discuss their thoughts on when joking about the death camps is appropriate or taboo. “Nazi humor, that’s OK. Holocaust humor, no,” Jewish comedic giant, actor and filmmaker Mel Brooks says in the film. “Anything I […]

    Read more →
  • Arts and Culture Blogs Tragedy Culminates in ‘Celebration,’ Says Israeli Author Who Lost Son to Terror

    Tragedy Culminates in ‘Celebration,’ Says Israeli Author Who Lost Son to Terror

    JNS.org – Sherri Mandell’s life was devastated on May 8, 2001, when her 13-year-old son Koby was murdered by terrorists on the outskirts of the Israeli Jewish community of Tekoa. Yet Mandell not only shares the story of her loss, but also celebrates the lessons she has learned from tragedy. Indeed, “celebrate” is this Israeli-American author’s word choice. Her second book, The Road to Resilience: From Chaos to Celebration (Toby Press), came out earlier this year. The lesson: in every celebration, there is […]

    Read more →